# Eledon Pharmaceuticals, Inc.: filings

ELDN · Nasdaq · CIK 1404281 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/eldn.md) · [Financials](/companies/eldn/financials.md) · [Filings](/companies/eldn/filings.md) · [Insiders](/companies/eldn/insiders.md)

## Reports and events: 212 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 160, 8-K 116, 3 44, 10-Q 36, SC 13G/A 25, UPLOAD 17, CORRESP 16, DEFA14A 16, SC 13G 16, SC 13D/A 14, DEF 14A 13, 10-K 12, EFFECT 12, S-3 9, S-8 9, D 8, 424B5 6, CT ORDER 6, SCHEDULE 13G/A 6, 10-K/A 5, 424B3 5, ARS 5, 8-K/A 4, PRE 14A 4, S-1 4, SC 13D 4, PRER14A 3, SCHEDULE 13G 3, 10-Q/A 2, DRS/A 2, IRANNOTICE 2, S-1/A 2, S-3/A 2, 424B2 1, 424B4 1, 8-A12B 1, 8-A12B/A 1, CERTNAS 1, DEFM14A 1, DRS 1, FWP 1, NT 10-Q 1, PREM14A 1, RW 1, S-1MEF 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-13 | 16:30 ET | [10-Q](/filings/0001193125-26-349314.md) | Quarterly report, period 2026-06-30 | 0001193125-26-349314 |
| 2026-08-13 | 16:08 ET | [8-K](/filings/0001193125-26-349170.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-349170 |
| 2026-06-22 | 17:00 ET | [8-K](/filings/0001193125-26-277653.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-277653 |
| 2026-05-13 | 16:20 ET | [10-Q](/filings/0001193125-26-221702.md) | Quarterly report, period 2026-03-31 | 0001193125-26-221702 |
| 2026-05-13 | 16:15 ET | [8-K](/filings/0001193125-26-221658.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-221658 |
| 2026-04-30 | 16:57 ET | [DEF 14A](/filings/0001193125-26-197732.md) | Proxy statement, period 2026-06-18 | 0001193125-26-197732 |
| 2026-03-19 | 17:05 ET | [10-K](/filings/0001193125-26-116164.md) | Annual report, period 2025-12-31 | 0001193125-26-116164 |
| 2026-03-19 | 17:02 ET | [8-K](/filings/0001193125-26-116154.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-116154 |
| 2026-01-02 | 16:30 ET | [8-K](/filings/0001193125-26-000968.md) | 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-000968 |
| 2025-11-14 | 17:11 ET | [8-K](/filings/0001193125-25-283294.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-283294 |
| 2025-11-14 | 17:05 ET | [10-Q](/filings/0001193125-25-283275.md) | Quarterly report, period 2025-09-30 | 0001193125-25-283275 |
| 2025-11-13 | 20:55 ET | [8-K](/filings/0001193125-25-278392.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-25-278392 |
| 2025-11-07 | 18:44 ET | [8-K](/filings/0001193125-25-270286.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-270286 |
| 2025-08-14 | 17:11 ET | [10-Q](/filings/0001193125-25-180906.md) | Quarterly report, period 2025-06-30 | 0001193125-25-180906 |
| 2025-08-14 | 17:08 ET | [10-Q/A](/filings/0001193125-25-180904.md) | Quarterly report, amended, period 2025-03-31 | 0001193125-25-180904 |
| 2025-08-14 | 16:46 ET | [10-K/A](/filings/0001193125-25-180865.md) | Annual report, amended, period 2024-12-31 | 0001193125-25-180865 |
| 2025-08-14 | 16:30 ET | [8-K](/filings/0001193125-25-180820.md) | 2.02 Results of operations; 4.02 Non-reliance on financial statements; 9.01 Financial statements and exhibits | 0001193125-25-180820 |
| 2025-08-06 | 16:03 ET | [8-K](/filings/0000950170-25-103975.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-103975 |
| 2025-06-12 | 17:28 ET | [8-K](/filings/0000950170-25-085588.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-25-085588 |
| 2025-05-14 | 17:00 ET | [10-Q](/filings/0000950170-25-071582.md) | Quarterly report, period 2025-03-31 | 0000950170-25-071582 |
| 2025-05-14 | 16:05 ET | [8-K](/filings/0000950170-25-071370.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-071370 |
| 2025-04-29 | 17:00 ET | [DEF 14A](/filings/0000950170-25-060299.md) | Proxy statement, period 2025-06-10 | 0000950170-25-060299 |
| 2025-04-14 | 17:00 ET | [8-K/A](/filings/0000950170-25-053765.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0000950170-25-053765 |
| 2025-04-07 | 17:00 ET | [8-K](/filings/0000950170-25-051663.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0000950170-25-051663 |
| 2025-03-20 | 17:00 ET | [10-K](/filings/0000950170-25-042754.md) | Annual report, period 2024-12-31 | 0000950170-25-042754 |
| 2025-03-20 | 16:05 ET | [8-K](/filings/0000950170-25-042644.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-042644 |
| 2024-12-20 | 08:00 ET | [8-K](/filings/0000950170-24-138782.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-24-138782 |
| 2024-11-12 | 17:00 ET | [10-Q](/filings/0000950170-24-125622.md) | Quarterly report, period 2024-09-30 | 0000950170-24-125622 |
| 2024-11-12 | 16:05 ET | [8-K](/filings/0000950170-24-125340.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-125340 |
| 2024-10-30 | 21:27 ET | [8-K](/filings/0000950170-24-118497.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-118497 |
| 2024-10-29 | 08:00 ET | [8-K](/filings/0000950170-24-117946.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-117946 |
| 2024-10-01 | 16:30 ET | [8-K](/filings/0000950170-24-110857.md) | 3.02 Unregistered sale of equity | 0000950170-24-110857 |
| 2024-09-20 | 17:00 ET | [8-K](/filings/0000950170-24-108465.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0000950170-24-108465 |
| 2024-08-19 | 16:36 ET | [10-Q](/filings/0000950170-24-098590.md) | Quarterly report, period 2024-06-30 | 0000950170-24-098590 |
| 2024-08-19 | 16:33 ET | [10-Q/A](/filings/0000950170-24-098582.md) | Quarterly report, amended, period 2024-03-31 | 0000950170-24-098582 |
| 2024-08-19 | 16:30 ET | [10-K/A](/filings/0000950170-24-098575.md) | Annual report, amended, period 2023-12-31 | 0000950170-24-098575 |
| 2024-08-14 | 17:15 ET | [8-K](/filings/0000950170-24-097206.md) | 2.02 Results of operations; 4.02 Non-reliance on financial statements; 9.01 Financial statements and exhibits | 0000950170-24-097206 |
| 2024-07-12 | 16:30 ET | [8-K](/filings/0000950170-24-083220.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0000950170-24-083220 |
| 2024-07-10 | 16:47 ET | [8-K](/filings/0000950170-24-082739.md) | 3.02 Unregistered sale of equity | 0000950170-24-082739 |
| 2024-07-10 | 16:41 ET | [8-K](/filings/0000950170-24-082730.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-082730 |
| 2024-05-30 | 16:05 ET | [DEF 14A](/filings/0000950170-24-066564.md) | Proxy statement, period 2024-07-10 | 0000950170-24-066564 |
| 2024-05-15 | 07:00 ET | [10-Q](/filings/0000950170-24-060025.md) | Quarterly report, period 2024-03-31 | 0000950170-24-060025 |
| 2024-05-13 | 16:30 ET | [8-K](/filings/0000950170-24-058706.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-058706 |
| 2024-05-07 | 07:15 ET | [8-K](/filings/0000950170-24-053934.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-053934 |
| 2024-04-26 | 17:00 ET | [10-K/A](/filings/0000950170-24-049277.md) | Annual report, amended, period 2023-12-31 | 0000950170-24-049277 |
| 2024-03-28 | 16:30 ET | [10-K](/filings/0000950170-24-038091.md) | Annual report, period 2023-12-31 | 0000950170-24-038091 |
| 2024-03-28 | 16:01 ET | [8-K](/filings/0000950170-24-038008.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-038008 |
| 2023-11-09 | 17:00 ET | [10-Q](/filings/0000950170-23-062203.md) | Quarterly report, period 2023-09-30 | 0000950170-23-062203 |
| 2023-11-09 | 16:05 ET | [8-K](/filings/0000950170-23-062007.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-062007 |
| 2023-11-02 | 16:30 ET | [8-K](/filings/0000950170-23-058279.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-23-058279 |

Page 1 of 5. [Older](/companies/eldn/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 30, 2026, 11:26 ET. No prices; not investment advice.